Derek Lowe
@dereklowe.bsky.social
Medicinal chemist / chemical biologist, author of “In the Pipeline” at http://science.org/blogs/pipeline. derekb.lowe@gmail.com and on Signal at Dblowe.18
All opinions are mine; I don’t speak for my employer in any way.
All opinions are mine; I don’t speak for my employer in any way.
Yeah right. And these goobers don’t even realize that some of that Latin (like Tacitus) is so allusive and compressed that you’re going to be shifting into low gear real fast.
November 11, 2025 at 4:32 AM
Yeah right. And these goobers don’t even realize that some of that Latin (like Tacitus) is so allusive and compressed that you’re going to be shifting into low gear real fast.
The company you wrote about sold the program to Anji Pharmaceuticals a few years later, and last I saw it (as ANJ900) was slowly working its way through more human trials. One gets the sense that there isn’t enough money to go faster.
November 10, 2025 at 10:27 PM
The company you wrote about sold the program to Anji Pharmaceuticals a few years later, and last I saw it (as ANJ900) was slowly working its way through more human trials. One gets the sense that there isn’t enough money to go faster.
Given the choice, I would rather be governed by those guys (and a cabinet of Juggalos) than the clowns we actually have.
November 10, 2025 at 10:14 PM
Given the choice, I would rather be governed by those guys (and a cabinet of Juggalos) than the clowns we actually have.
And everyone who understands the uniqueness of American public research funding! It’s a disastrously self-destructive move.
November 7, 2025 at 4:22 AM
And everyone who understands the uniqueness of American public research funding! It’s a disastrously self-destructive move.
Cash price on Ozempic (no insurance) was actually $499/month, not the price quoted in the press release
November 6, 2025 at 9:06 PM
Cash price on Ozempic (no insurance) was actually $499/month, not the price quoted in the press release